RYVU THERAPEUTICS ZY-40/ PLSELVT00013 /
| 15/11/2024 07:57:05 | Chg. -0.2000 | Volume | Bid22:00:00 | Demandez à22:00:00 | Capitalisation boursière | Dividende Y. | Rapport P/E |
|---|---|---|---|---|---|---|---|
| 11.0000EUR | -1.79% | - Chiffrre d'affaires: - |
10.0400Bid taille: 400 | 11.1000Ask la taille: 400 | 243.13 Mio.EUR | - | - |
GlobeNewswire
11/12/2023
Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Me...
GlobeNewswire
07/12/2023
Ryvu Therapeutics Presents Data on RVU120 at the San Antonio Breast Cancer Symposium 2023
GlobeNewswire
29/11/2023
Ryvu Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire
23/10/2023
Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Soli...
GlobeNewswire
04/10/2023
Ryvu Therapeutics to Present Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2...
GlobeNewswire
13/09/2023
Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update
GlobeNewswire
25/06/2021
Roth Capital Partners to Host a Virtual Healthcare Private Company Forum on June 28, 2021
